DCM

DAFNA Capital Management Portfolio holdings

AUM $524M Turnover 22.92%
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+9.25%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$398M
AUM Growth
+$20.8M
Cap. Flow
+$11.1M
Cap. Flow %
2.8%
Top 10 Hldgs %
51.36%
Holding
92
New
12
Increased
23
Reduced
18
Closed
5
Avg Time Held
2 years
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
1.7 years

Top Buys

Rank Stock Value
1
CBAY icon
Cymabay Therapeutics
CBAY
+$4.8M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$3.99M
3
AXGN icon
Axogen
AXGN
+$3.98M
4
ACET icon
Adicet Bio
ACET
+$3.83M
5
BMEA icon
Biomea Fusion
BMEA
+$3.32M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$11.8M
2
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$3.81M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$2.74M
4
AFMD icon
Affimed
AFMD
+$2.43M
5
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$1.83M

Sector Composition

Rank Sector Weight
1 Healthcare 97.15%
2 Miscellaneous 2.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
STXS icon
1
Stereotaxis
STXS
$104M
$84.8M 21.33%
13,680,554
– –
2013 Q2
34 quarters
BPMC icon
2
DELISTED
Blueprint Medicines
BPMC
$22.2M 5.57%
206,911
– –
2016 Q4
20 quarters
FATE icon
3
Fate Therapeutics
FATE
$231M
$21.8M 5.48%
372,160
+27,800
+8% +$1.58M
2019 Q2
10 quarters
ACET icon
4
Adicet Bio
ACET
$45.6M
$12.8M 3.22%
45,823
+22,305
+95% +$3.83M
2020 Q3
5 quarters
XENE icon
5
Xenon Pharmaceuticals
XENE
$3.27B
$12.6M 3.16%
402,667
-3,868
-1% -$116K
2015 Q3
25 quarters
ARNA
6
DELISTED
Arena Pharmaceuticals Inc
ARNA
$11.1M 2.8%
119,615
– –
2018 Q1
15 quarters
IDYA icon
7
IDEAYA Biosciences
IDYA
$3.26B
$10.9M 2.73%
460,061
– –
2020 Q3
5 quarters
DXCM icon
8
DexCom
DXCM
$31.5B
$9.74M 2.45%
72,552
-12,000
-14% -$1.72M
2017 Q3
17 quarters
KRTX icon
9
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$9.49M 2.39%
72,423
-2,162
-3% -$279K
2020 Q1
7 quarters
NRIX icon
10
Nurix Therapeutics
NRIX
$2.58B
$8.87M 2.23%
306,320
– –
2021 Q1
3 quarters
MORF icon
11
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$8.6M 2.16%
181,467
– –
2020 Q4
4 quarters
BHVN icon
12
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$8.01M 2.01%
58,100
-30,000
-34% -$3.81M
2018 Q2
14 quarters
SAGE icon
13
DELISTED
Sage Therapeutics
SAGE
$7.67M 1.93%
180,306
– –
2017 Q4
16 quarters
MRUS icon
14
DELISTED
Merus
MRUS
$7.19M 1.81%
226,089
+94,140
+71% +$2.66M
2021 Q1
3 quarters
NBIX icon
15
Neurocrine Biosciences
NBIX
$13.8B
$7.13M 1.79%
83,655
-1,000
-1% -$92K
2016 Q1
23 quarters
SNDX icon
16
Syndax Pharmaceuticals
SNDX
$1.21B
$6.49M 1.63%
296,535
+215,833
+267% +$3.99M
2020 Q2
6 quarters
IBB icon
17
iShares Biotechnology ETF
IBB
$10.4B
$6.24M 1.57%
40,900
– –
2016 Q4
20 quarters
CYTK icon
18
Cytokinetics
CYTK
$8.81B
$6.11M 1.54%
134,094
-40,906
-23% -$1.58M
2021 Q3
1 quarter
CBAY icon
19
DELISTED
Cymabay Therapeutics
CBAY
$6.04M 1.52%
1,787,569
+1,263,283
+241% +$4.8M
2021 Q1
3 quarters
CSII
20
DELISTED
Cardiovascular Systems, Inc.
CSII
$5.39M 1.36%
286,988
+93,247
+48% +$2.49M
2018 Q2
14 quarters
RVMD icon
21
Revolution Medicines
RVMD
$41.4B
$5.34M 1.34%
212,231
+2,500
+1% +$70.5K
2020 Q4
4 quarters
ATRC icon
22
AtriCure
ATRC
$2.91B
$5.01M 1.26%
72,029
– –
2013 Q2
34 quarters
RCUS icon
23
Arcus Biosciences
RCUS
$2.87B
$4.74M 1.19%
117,200
-6,500
-5% -$252K
2020 Q1
7 quarters
LITS icon
24
Lite Strategy Inc
LITS
$35.6M
$4.71M 1.18%
88,242
+56,192
+175% +$3.13M
2020 Q2
6 quarters
ISEE
25
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.61M 1.16%
275,976
+59,625
+28% +$977K
2020 Q2
6 quarters
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, DAFNA Capital Management held 92 positions worth $398M, up 5.5% from $377M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DAFNA Capital Management's Q4 2021 filing shows 12 new, 23 increased, 18 reduced and 5 closed positions. Its largest new stake was Axogen: 332,103 shares worth $3.11M. The largest sale was Dicerna Pharmaceuticals, Inc., an estimated $11.8M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Miscellaneous.

  • DAFNA Capital Management's largest Q4 2021 buy was Axogen: 332,103 shares worth $3.11M.
  • DAFNA Capital Management added most to Cymabay Therapeutics in Q4 2021, an estimated $4.8M increase.
  • DAFNA Capital Management's biggest Q4 2021 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $3.81M.
  • DAFNA Capital Management fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $11.8M.
  • DAFNA Capital Management's ten largest holdings make up 51% of its $398M portfolio in Q4 2021.
  • DAFNA Capital Management opened 12 new positions and closed 5 in Q4 2021.
  • DAFNA Capital Management's portfolio value rose 5.5% quarter-over-quarter to $398M.

Based on DAFNA Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.